86 Taking all RCTs together, re-starting OAC was associated with reduced risk of ischemic stroke on the one hand, but increased risk (of borderline significance) for recurrent intracranial bleeding (ICB). 87 The threat of ICH recurrence is daunting, but many physicians will consider restarting anti-thrombotic therapy at least 30 days after the ICH. 88 The results of ongoing RCTs focusing on OAC vs no anticoagulation (without considering LAAC) in ICH patients with AF (such as ENRICH-AF, 89 PRESTIGE-AF, 90 A 3 ICH, 91 STATICH 92 and ASPIRE 93 ) are awaited.
1
—
—